Kurt Kamrud has more than 25 years of experience in molecular virology. Since joining SGI in 2013, he has led the company’s self-amplifying RNA replicon platform development program. Before joining SGI, Dr. Kamrud was Director of the Discovery Group at AlphaVax Inc. in the Research Triangle Park, Durham, NC. AlphaVax was focused on development of an alphavirus replicon-particle platform for human vaccine development. Dr. Kamrud lead a team that developed the alphavirus replicon vaccine technology, pushed vaccine targets through pre-clinical testing and transferred these targets to the manufacturing group to support cGMP vaccine production. The AlphaVax replicon-particle technology was advanced through Phase 2 human clinical trials. After 10 years at AlphaVax, Dr. Kamrud became Vice President of Research and Chief Scientific Officer at Harrisvaccines in Ames, IA. Harrisvaccines is a veterinary vaccine company focused on alphavirus replicon particle-based vaccines. While at Harrisvaccines, Dr. Kamrud successfully lead the effort to fully license alphavirus replicon particle-based vaccines for veterinary use with the USDA. Harrisvaccines was acquired by Merck Animal Health in 2016.
Dr. Kamrud received his Ph.D. in Microbiology (molecular virology) from Colorado State University. Prior to earning his Ph.D. he earned a M.S. in Microbiology from Hood College and a B.A. in Computer Science and Biology from Concordia College.